Wgi-0301
Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.Phase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
520 Active assets in the Advanced Hepatocellular Carcinoma (HCC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adefovir Bukwang Pharmaceutical | Phase 4 | BBB |
Huaier Granule Tongji Hospital | Phase 4 | BBB |
Sorafenib Bayer | Phase 4 | BBB |
Carboplatin AstraZeneca | Phase 4 | BB |
Theprubicin RWTH Aachen University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Wgi-0301 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →